Effects of pentoxifylline on differentiation, maturation, and function of human CD14+ monocyte-derived dendritic cells

Journal of Immunotherapy

Volumn 30, Issue 1, 2007, Pages 89-95

  Zhang, Rongxin ^a   Bharadwaj, Uddalak ^a   Li, Min ^a   Chen, Changyi ^a   Yao, Qizhi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cytokine; DC differentiation and activation; Endocytosis; MLR; Pentoxifylline

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFECT; ENDOCYTOSIS; HUMAN; HUMAN CELL; IMMUNOREGULATION; INTERFERON PRODUCTION; MIXED LYMPHOCYTE REACTION; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD14; CELL DIFFERENTIATION; DENDRITIC CELLS; HUMANS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MONOCYTES; PENTOXIFYLLINE; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846009117     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000211323.53396.38     Document Type: Article

References (34)

1. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987;34:50-97.
2. Schwarz A, Krone C, Trautinger F, et al. Pentoxifylline suppresses irritant and contact hypersensitivity reactions. J Invest Dermatol. 1993;101:549-552.
3. Gillings DB. Pentoxifylline and intermittent claudication: review of clinical trials and cost-effectiveness analyses. J Cardiovasc Pharmacol. 1995;25(Suppl 2):S44-S50.
4. Nataf S, Louboutin JP, Chabannes D, et al. Pentoxifylline inhibits experimental allergic encephalomyelitis. Acta Neurol Scand. 1993;88:97-99.
5. Bianco JA, Appelbaum FR, Nemunaitis J, et al. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood. 1991;78:1205-1211.
6. Zabel P, Wolter DT, Schonharting MM, et al. Oxpentifylline in endotoxaemia. Lancet. 1989;2:1474-1477.
7. Coimbra R, Melbostad H, Hoyt DB. Effects of phosphodiesterase inhibition on the inflammatory response after shock: role of pentoxifylline. J Trauma. 2004;56:442-449.
8. Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun. 1988;155:1230-1236.
9. Zabel P, Schade FU, Schlaak M. Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology. 1993;187:447-463.
10. Seldon PM, Barnes PJ, Meja K, et al. Suppression of lipopolysaccharide- induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Mol Pharmacol. 1995;48:747-757.
11. Neuner P, Klosner G, Pourmojib M, et al. Pentoxifylline in vivo and in vitro down-regulates the expression of the intercellular adhesion molecule-1 in monocytes. Immunology. 1997;90:435-439.
12. Klahr S, Morrissey J. Progression of chronic renal disease. Am J Kidney Dis. 2003;41:S3-S7.
13. Hecht M, Muller M, Lohmann-Matthes ML, et al. In vitro and in vivo effects of pentoxifylline on macrophages and lymphocytes derived from autoimmune MRL-lpr/lpr mice. J Leukoc Biol. 1995;57:242-249.
14. Wang W, Tam WF, Hughes CC, et al. c-Rel is a target of pentoxifylline-mediated inhibition of T lymphocyte activation. Immunity. 1997;6:165-174.
15. Kovach NL, Lindgren CG, Fefer A, et al. Pentoxifylline inhibits integrin-mediated adherence of interleukin-2- activated human peripheral blood lymphocytes to human umbilical vein endothelial cells, matrix components, and cultured tumor cells. Blood. 1994;84:2234-2242.
16. Gonzalez-Amaro R, Portales-Perez D, Baranda L, et al. Pentoxifylline inhibits adhesion and activation of human T lymphocytes. J Immunol. 1998;161:65-72.
17. Rott O, Charreire J, Semichon M, et al. B cell superstimulatory influenza virus (H2-subtype) induces B cell proliferation by a PKC-activating, Ca(2+)-independent mechanism. J Immunol. 1995;154:2092-2103.
18. Wang W, Rath S, Durdik JM, et al. Pentoxifylline inhibits Ig kappa gene transcription and rearrangements in pre-B cells. J Immunol. 1998;160:1789-1795.
19. Janeway CA Jr, Bottomly K. Signals and signs for lymphocyte responses. Cell. 1994;76:275-285.
20. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233-258.
21. Dustin ML, Olszowy MW, Holdorf AD, et al. A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts. Cell. 1998;94:667-677.
22. Marlin SD, Springer TA. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell. 1987;51:813-819.
23. Grakoui A, Bromley SK, Sumen C, et al. The immunological synapse: a molecular machine controlling T cell activation. Science. 1999;285:221-227.
24. Monks CR, Freiberg BA, Kupfer H, et al. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature. 1998;395:82-86.
25. Rieckmann P, Weber F, Gunther A, et al. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol. 1996;64:193-200.
26. Chen YM, Chien CT, Hu-Tsai MI, et al. Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney Int. 1999;56:932-943.
27. Segura E, Nicco C, Lombard B, et al. ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood. 2005;106:216-223.
28. Heystek HC, Thierry AC, Soulard P, et al. Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity. Int Immunol. 2003;15:827-835.
29. Shakhar G, Lindquist RL, Skokos D, et al. Stable T cell-dendritic cell interactions precede the development of both tolerance and immunity in vivo. Nat Immunol. 2005;6:707-714.
30. Peterson TC, Isbrucker RA, Hooper ML. In vitro effect of platelet-derived growth factor on fibroproliferation and effect of cytokine antagonists. Immunopharmacology. 1994;28:259-270.
31. Duncan MR, Hasan A, Berman B. Pentoxifylline, pentifylline, and interferons decrease type I and III procollagen mRNA levels in dermal fibroblasts: evidence for mediation by nuclear factor 1 down-regulation. J Invest Dermatol. 1995;104:282-286.
32. Tsai TJ, Lin RH, Chang CC, et al. Vasodilator agents modulate rat glomerular mesangial cell growth and collagen synthesis. Nephron. 1995;70:91-99.
33. Yang KD, Chuen HL, Shaio MF. Pentoxifylline augments but does not antagonize TNF alpha-mediated neuroblastoma cell differentiation: modulation of calcium mobilization but not cAMP. Biochem Biophys Res Commun. 1995;211:1006-1014.
34. Moller DR, Wysocka M, Greenlee BM, et al. Inhibition of human interleukin-12 production by pentoxifylline. Immunology. 1997;91:197-203.